Trial Profile
A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2023
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Ezetimibe; Rosuvastatin; Simvastatin
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Registrational
- Acronyms APPRISE; ODYSSEY APPRISE
- Sponsors Sanofi
- 01 Jan 2023 Results evaluating lipid-lowering efficacy and safety of alirocumab in a real-life setting in France, published in the Archives of Cardiovascular Diseases
- 01 Nov 2022 Results of sub-group analysis assessing efficacy and safety of alirocumab in patients with hypercholesterolemia and high CV risk in a real-life setting, published in the Nutrition, Metabolism and Cardiovascular Diseases.
- 22 Sep 2021 Results (n=68) of an analysis from Belgian cohort of this trial published in the International Journal of Clinical Practice